|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Amgen’s (AMGN) product portfolio includes the blockbuster drugs Prolia, Enbrel, Neulasta, Xgeva, Aranesp, Sensipar/Mimpara, Kyprolis, and Epogen. Blockbuster drug Neulasta (pegfilgrastim) reported a 1% rise in revenue to $1.10 billion during the second quarter compared to ~$1.09 billion in the second quarter of 2017.
St. Charles County has filed a lawsuit against a group of pharmaceutical manufacturers and drug distributors, accusing them of "aggressive and fraudulent marketing" of prescription opioid painkillers that has led to a drug abuse epidemic.
Five cannabis industry executives laid out their business models and viewpoints Friday at the Benzinga Cannabis Capital Conference in Toronto. Zoning laws and regulations are some of the biggest challenges for cannabis dispensaries, Vahan Ajamian, MedMen's (OTC: MMNFF) managing director of analyst relations, said during the conference.
Major pharmaceutical companies are partying like it’s 2001. U.S. drugmakers including Pfizer Inc., Eli Lilly & Co., and Merck & Co. are seeing their share prices balloon to the highest levels in more than 16 years as investors rotate in after second-quarter results proved stronger than expected. Impressive earnings paired with waning concerns about potential Trump administration actions on drug pricing could be helping to draw generalist investors in a bit of a “catch up trade,” according to Credit Suisse analyst Vamil Divan.
The size of Johnson & Johnson (NYSE:JNJ), a US$360.75b large-cap, often attracts investors seeking a reliable investment in the stock market. Big corporations are much sought after by risk-averse investorsRead More...
Array BioPharma (ARRY) is developing a number of combination therapies with its investigational MEK inhibitor binimetinib with PD-1/PD-L1 checkpoint inhibitors. The company is conducting the trials in collaboration with Bristol-Myers Squibb (BMY), Pfizer (PFE), and Merck (MRK). During its fourth-quarter and full-fiscal 2018 earnings release on August 14, Array Biopharma provided updates on these trials.
Allergan’s (AGN) International Business segment includes the revenues from both its specialized therapeutics portfolio and its general products portfolio from outside US markets.
Mylan (MYL) made a downward revision to its fiscal 2018 guidance during its second-quarter earnings release on August 8. A major factor driving down the company’s performance was lower North America sales due to volume declines in the company’s existing products. Due to the impact of “turbulence in the U.S. and the disturbing trends regarding access to complex products,” Mylan lowered its fiscal 2018 guidance during its second-quarter earnings release on August 8.
Mathai Mammen, Global Head, Janssen Research & Development and Lesley Fishman, Senior Director Investor Relations will host the call. The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of the webcast will be available approximately three hours after the conference call concludes.
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts on Monday, August 27, 2018 at 9:00 a.m. EDT. Information on accessing and pre-registering for the webcast will be available at www.pfizer.com/investors beginning today. Visitors to www.pfizer.com/investors will be able to view and listen to an archived copy of the webcast of the conference call.
Mylan (MYL) ended the second quarter with cash and cash equivalents of $330.2 million. This compared to the net cash provided by operating activities of $1.02 billion available to the company by the end of the fiscal second quarter of 2017. For the six months ended June 30, Mylan’s adjusted free cash flows were $1.3 billion, up ~22% YoY (year-over-year).
Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.